Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 6/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | FAM20C | Q8IXL6 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31672509 | 1.00 | KDR (0.41) | KDRBRD4IGF1RFGFR1METAP2 | |
| SCHEMBL31672486 | 0.88 | KDR (0.46) | KDRBRD4IGF1RFAM20CEGFR | |
| SCHEMBL1116469 | 0.88 | KDR (0.46) | KDRBRD4IGF1RFAM20CEGFR | |
| SCHEMBL31672403 | 0.85 | KDR (0.44) | KDRBRD4IGF1RFGFR1FAM20C | |
| SCHEMBL1116463 | 0.85 | KDR (0.44) | KDRBRD4IGF1RFGFR1FAM20C | |
| SCHEMBL590349 | 0.84 | KDR (0.49) | KDRBRD4IGF1RFAM20CEGFR | |
| SCHEMBL30454194 | 0.84 | KDR (0.49) | KDRBRD4IGF1RFAM20CEGFR | |
| SCHEMBL588511 | 0.83 | TNNI3K (0.49) | KDRBRD4IGF1RFAM20CEGFR | |
| SCHEMBL30453077 | 0.83 | TNNI3K (0.49) | KDRBRD4IGF1RFAM20CEGFR | |
| SCHEMBL589718 | 0.78 | METAP2 (0.37) | KDRMETAP2MAPK1EGFRGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311825-B1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-20120277258-A1 | Chemical Compounds | LEO OSPREY LIMITED (JE) | 2012-11-01 | — | — | US | disclosed |
| US-20120277258-A1 | Chemical Compounds | LEO OSPREY LIMITED (JE) | 2012-11-01 | — | — | US | disclosed |
| US-8114885-B2 | Pazopanib hydrochloride and synthesis, chemical intermediates, and dosage forms thereof; anticancer; colon cancer, breast cancer | GLAXOSMITHKLINE LLC (US) | 2012-02-14 | — | — | US | disclosed |
| US-7858626-B2 | Pyrimidineamines as angiogenesis modulators | GLAXOSMITHKLINE LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858626-B2 | Pyrimidineamines as angiogenesis modulators | GLAXOSMITHKLINE LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100105712-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-04-29 | — | — | US | disclosed |
| US-20070292513-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-12-20 | — | — | US | disclosed |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-11-22 | — | — | US | disclosed |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-11-22 | — | — | US | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015756-A1 | Chemical compounds | KDR, FLT4, FLT1 | KDR 1/4885BRD4 594/4885IGF1R 488/4885 |
| US-20100105712-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | KDR 1/4885BRD4 594/4885IGF1R 488/4885 |
| US-20120277258-A1 | Chemical Compounds | KDR, FLT4, FLT1 | KDR 1/4885BRD4 594/4885IGF1R 488/4885 |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | KDR 1/4885BRD4 594/4885IGF1R 488/4885 |
| US-20070292513-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | KDR 1/4885BRD4 594/4885IGF1R 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.